NORTH CHICAGO - An analysis from AbbVie's (NYSE: ABBV) three-year, 28-country MEASURE-AD study revealed that people living with moderate to severe atopic dermatitis (an immune-mediated skin disease) who are not receiving systemic therapy had greater clinical, psychosocial and economic burdens compared to those receiving systemic therapy.1

A separate analysis from the MEASURE-AD study demonstrated that better quality of life as measured by Dermatology Life Quality Index (DLQI) scores and lower disease severity scores were associated with lower clinical burden and work impairment.2 Results from the MEASURE-AD subanalyses were featured at the 31st European Academy of Dermatology and Venereology (EADV) Hybrid Congress onsite in Milan and online from September 7-10 as a poster and an oral presentation.

'Results from MEASURE-AD broaden awareness of the continued burden that people living with atopic dermatitis experience every day and of the potential link between disease severity, treatment approach and overall impact on patient-reported quality of life,' said Juan Francisco Silvestre, M.D., attending dermatologist, General University Hospital of Alicante in Alicante, Spain, and investigator for the MEASURE-AD study. 'These real-world analyses underscore the multidimensional burden of atopic dermatitis and the need for more therapeutic options for patients.'

Evaluation of Real-World Burden for Moderate to Severe Atopic Dermatitis in Patients with or without Systemic Therapy

This post-hoc analysis titled, 'Real-World Burden in Patients with Atopic Dermatitis Who Are Candidates for Systemic Therapy and Currently Receiving No Systemic Therapy, No Treatment, Topical Therapy Only, or Systemic Therapy: Results from a Real-World Multicountry Study,' showed greater clinical, psychosocial and economic burden among adult patients with moderate to severe atopic dermatitis not receiving systemic therapy versus those receiving systemic therapy.1 Additionally, data suggested that many patients living with atopic dermatitis may be undertreated, with only half of eligible patients receiving systemic therapy.1

Mean disease severity scores across six measures were higher for patients receiving no systemic therapy versus those receiving systemic therapy (all p

(C) 2022 Electronic News Publishing, source ENP Newswire